Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 82Lung Neoplasms 24Brain Neoplasms 6NSCLC 5Meningeal Carcinomatosis 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non Small Cell Lung Cancer Metastatic 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage II-IIIB Non-small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Rectal Neoplasms 1Rare Tumour 1Non-Small Cell Lung Cancer With EGFR T790M Mutation 1Neurocognitive 1Melanoma 1Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1Glioma 1

Interventions

Paclitaxel 2Injections 2toripalimab 1tislelizumab 1surufatinib 1sotorasib 1osimertinib 1netrin-1 inhibitor NP137 1lazertinib 1fluzoparib 1camrelizumab 1Panitumumab 1PM 01183 1Nivolumab 1Ipilimumab 1HMPL-013 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bevacizumab 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumors × osimertinib × Clear all
NCT06895928 2025-04-22

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡